Thymosin Beta-4: The Whole Molecule Behind TB-500

What Is Thymosin Beta-4?

Thymosin Beta-4 is a 43-amino-acid protein present in nearly every cell in the body and in high concentration in platelets and in the fluid of healing wounds. It was first isolated from thymus tissue, which gave it its name — a name that has aged poorly, since it turned out to be nearly ubiquitous rather than thymic.

Its principal known function is binding actin, the protein that forms the internal scaffolding cells use to change shape and move.

The fragment relationship, in plain language: the difference between Thymosin Beta-4 and TB-500 is the difference between a full sentence and the clause that carries its meaning. Researchers identified the specific region of the molecule responsible for actin binding and cell migration, and TB-500 is that region synthesised on its own. Shorter, cheaper to make, more stable — and, importantly, not identical. Most published research describes work on the full molecule, while much of what is sold and discussed is the fragment. Papers about one are frequently cited as evidence for the other.

What the Research Examines

The foundational work is Malinda and colleagues in 1999, reporting that skin cells migrated two to three times faster in the presence of Thymosin Beta-4 in culture, at concentrations as low as picograms. That potency at very low concentration is what put the molecule on the regenerative research map.

Subsequent literature discusses cardiac injury models and corneal repair. The Sosne review cited here summarises corneal research; it is not itself a clinical trial and does not establish human efficacy.

The honest framing: most published work concerns thymosin beta-4 itself, and the 17–23 fragment appears mainly within studies of the parent molecule. Neither holds regulatory approval.

Frequently Asked Questions

Published References

1. Malinda KM, Sidhu GS, Mani H, et al. “Thymosin beta4 accelerates wound healing.” The Journal of investigative dermatology, 1999. PubMed
2. Goldstein AL, Hannappel E, Kleinman HK. “Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues.” Trends in molecular medicine, 2005. PubMed
3. Bock-Marquette I, Saxena A, White MD, et al. “Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair.” Nature, 2004. PubMed
4. Sosne G, Qiu P, Kurpakus-Wheater M. “Thymosin beta 4: A novel corneal wound healing and anti-inflammatory agent.” Clinical ophthalmology (Auckland, N.Z.), 2007. PubMed
   A 2007 review in Clinical Ophthalmology. This replaces an unverified citation with a different, verified review; it is not a primary clinical trial.